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Lung cancer is the most common cancer worldwide and
the ﬁfth most common cause of death globally. Its inci-
dence continues to increase, especially within low- and
middle-income countries (LMICs), which have limited ca-
pacity to address the growing need for treatment. The
standard of care for lung cancer treatment often involves
radiation therapy (RT), which plays an important thera-
peutic role in curative-intent treatment of early-stage to
locally advanced disease, as well as in palliation. The
infrastructure, equipment, and human resources required
for RT may be limited in LMICs. However, this narrative
review discusses the scope of the problem of lung cancer
in LMICs, the role of RT technologies in lung cancer
treatment, and RT capacity in developing countries. Stra-
tegies are presented for maximizing the availability and
impact of RT in settings with minimal resource availability,
and areas for potential future innovation are identiﬁed.
Priorities for LMICs involve increasing access to RT
equipment and trained health care professionals, ensuring
quality of care, providing guidance on priority setting with
limited resources, and encouraging innovation to increase
the economic efﬁciency of RT delivery. Several interna-
tional initiatives are currently under way and represent
important ﬁrst steps toward scaling up RT in LMICs to
treat lung cancer.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.Keywords: Lung cancer; Non–small cell lung cancer; Global
health; Radiotherapy; Low- and middle-income countries;
QualityIntroduction: scope of the problem
Since 1985, the global incidence of and mortality
related to lung cancer have surpassed those of all other
cancers.1 In 2010, lung cancer (approximately 85% of
which is non–small cell lung cancer [NSCLC]2) was
ranked as the ﬁfth most common cause of death globally,
ahead of HIV/AIDS (sixth), tuberculosis (10th), and
malaria (11th).3 The projected increases in total inci-
dence of cancer over the next 15 years (to 2030)
are expected to be proportionally higher in low- and
middle-income countries (LMICs). The relatively recentJournal of Thoracic Oncology Vol. 11 No. 1: 21-29
22 Rodin et al Journal of Thoracic Oncology Vol. 11 No. 1and increasing spread of tobacco use in LMICs means
that the current lung cancer epidemic in these regions
has not yet reached its peak, and rates will likely
continue to rise for the next few decades.4,5 Environ-
mental factors, including air pollution,5 contamination of
drinking water with arsenic, and workplace exposure to
arsenic in industries such as mining,6 are also contrib-
uting to this transition in the epidemiology of lung
cancer.
RT plays a critical role in the treatment of lung can-
cer, with rates of RT use as high as 70% in some set-
tings.7 Global variation in the availability and use of RT is
substantial, however. This article discusses the role of
modern RT in treatment of NSCLC and reviews the
availability of RT in developing countries, as well as in
geographically underserviced regions of developed
countries. Finally, strategies for maximizing the avail-
ability and impact of RT in settings with minimal
resource availability are presented.
Role of RT in the treatment of NSCLC
RT plays an important role in the treatment of
NSCLC throughout the continuum of care, including in
radical treatment of early-stage and locally advanced
disease and in palliative care. Although surgery has
been the mainstay of treatment for early-stage lung
cancer, early-stage disease probably represents a mi-
nority of cases in LMICs, as it does in high-income
countries (HICs).8 In order of increasing complexity,
nonoperative options for curative-intent treatment
of stage I NSCLC include conventional radiotherapy
(i.e., 2 Gy delivered daily for several weeks), altered
fractionation schemes, and stereotactic radiation.Figure 1. (A) An illustration of the concept of two-dimensional
the upper mediastinum and neck and would be placed using ana
be treated with opposing anterior and posterior beams. (B) A
treatment, with the ﬁeld borders (blue) superimposed.Delivery of curative-intent radiotherapy to patients
who would otherwise go untreated is associated with
improved survival.9,10
In patients with locally advanced disease, RT plays
an important role as a component of dual-modality
therapy alongside chemotherapy and, in very select
patients, trimodality therapy, including surgery. RT also
plays a key role in the palliation of disease in the thorax,
as well as in the treatment of distant metastatic disease
in the brain, bone, and other regions. Palliative RT has
been found to improve symptoms of chest pain and
hemoptysis by 60% to 80% and cough and dyspnea by
50% to 70%,11 as well as to result in signiﬁcant
improvement in other symptoms of systemic disease.
Palliative thoracic RT in doses of 30 Gy in 10 fractions or
higher have been associated with improved survival in
patients with good performance status,12 but adequate
symptom control can still be achieved with shorter
regimens such as 20 Gy in ﬁve fractions or 10 Gy in a
single fraction.13
RT technology
Before the mid-1990s, RT planning relied on two-
dimensional imaging, with simple treatment ﬁelds
designed using radiography or ﬂuoroscopy (Fig. 1A).14
Square or rectangular ﬁelds could be delivered without
any modiﬁcation of the beam, but more complex shaping
of the beam required the creation of metal blocks (Fig. 2)
that would be placed in the treatment ﬁeld to attenuate
the beam. In that era, patient setup before treatment was
based on tattoo marks placed on the skin, with sub-
sequent adjustment of the patient’s position on the
basis of radiographic images—called portal imagestreatment planning. The ﬁeld borders (blue line) encompass
tomy visible on radiographs or ﬂuoroscopy. The patient would
n electronic portal image showing a patient at the time of
Figure 2. Blocks used for beam shaping. These hand-poured
metal blocks are placed into the treatment machine to
attenuate the beam in selected areas.
January 2016 RT for NSCLC in Minimal Resource Settings 23(see Fig. 1B)—taken on the treatment machine. Although
most centers in HICs now use more advanced tech-
niques, even RT with two-dimensional (2D) planning
and block creation is still unavailable in some LMICs and
underserviced areas.
The development of three-dimensional conformal RT
(3D-CRT) and intensity-modulated RT (IMRT) in the
1990s allowed better delineation of normal structures
(termed organs at risk) and target volumes (see Fig. 3).15
Although IMRT allows more advanced manipulation of
the radiation beam to provide more conformal radiation
plans, randomized data to conﬁrm its clinical superiority
over 3D-CRT techniques are not available. In many cases,
good outcomes can be achieved with less-advanced
techniques; for example, a prospective study of hypo-
fractionation using 3D-CRT in patients with medically
inoperable stage I (T1–2N0, <4 cm) NSCLC yielded re-
sults that were comparable to those reported with ste-
reotactic body RT and limited resection.16
Technologies for patient positioning have also
improved, with several imaging modalities available toFigure 3. Radiation treatment planning and delivery for stage I
volumes are outlined on a planning computed tomography (C
involved nodes are outlined (blue), and margins added for m
planning target volume (red color wash). The prescription dose
and 50% dose line (thin white) are shown. Normal structures a
are shown). For treatment delivery, a cone beam computed to
planning computed tomographic image (Panel C, main image)ensure accurate setup. Although tattoos and matching to
bony structures by means of electronic portal images are
still used, more advanced technologies involve orthogonal
radiographs with automated repositioning or cone beam
computed tomography (see Fig. 3C), which allows visu-
alization and matching of soft tissues. The application of
advanced technologies in settings with insufﬁcient
training or experience has been associated with outcomes
inferior to those of older, traditional approaches, how-
ever.17 Furthermore, the incremental beneﬁt of each small
improvement in RT technology is often not quantiﬁed.
RT capacity
Sufﬁcient RT capacity is necessary for cancer treat-
ment globally and in LMICs in particular, where only one-
third of RTmachines, but 60%of theworld’s patients with
cancer, are located.18 The modern delivery of RT is also
dependent on broader health system resources, including
imaging, pathology, laboratory medicine, and surgical fa-
cilities, to facilitate staging anddiagnosis and complete the
continuum of care.19 Increasing the infrastructure,
equipment, and human personnel able to deliver RT is a
critical step.18,20,21 We therefore summarize RT capacity
in the global regions of Europe, Africa, Asia, Latin America,
and North America from the standpoint of these three key
elements (Table 1). The numbers are based on available
published data and are subject to change.
Europe
Infrastructure. Major RT differences in capacity exist
between Western Europe and Southern/Eastern
Europe.22 Of the 1286 active RT centers registered with
the Directory of Radiotherapy Centres (DIRAC) database
in 2012, more than two-thirds were located in ﬁve West-
ernEuropean countries: Germany, Italy, France, theUnited
Kingdom, and Spain. The remaining RT centers were in
smaller countries with lower gross national income (GNI)
in southern and Eastern Europe. This socioeconomicII non–small cell lung cancer. Normal tissues and tumor target
T) scan (Panel A, axial; Panel B, coronal). The tumor and
icroscopic extension (green) and setup error produce the
is 60 Gy in 30 fractions, and the 95% dose line (thick yellow)
re also outlined (left lung, esophagus, heart, and spinal cord
mographic image (Panel C, inset) is acquired aligned to the
to conﬁrm positioning.
Table 1. Summary of radiotherapy capacity in Europe, Africa, Asia, Latin America and the Caribbean, and North America
Infrastructure Equipment Human resources Comments
Europe 1286 RT centers; more than
two-thirds in Germany,
Italy, France, the United
Kingdom, and Spain
3157 MV machines represent
19% of unmet need; 92%
of machines are linear
accelerators
6000 radiation oncologists,
3000 medical physicists,
and 10,000 RT technologists
Range of RT capacity follows
GNI distribution; many
centers perform advanced
RT techniques (IMRT, SABR)
Africa 160 RT centers; 29 countries
(20% of population) do not
have any machines
277 MV machines, 68% linear
accelerators; machines
weighted heavily toward
South Africa (33%) and
Egypt (27%)
No up-to-date data on
number of RT professionals;
presence of training
facilities noted in only 7
countries
Little known about types of
plans delivered
Asia 1462 RT centers; 86% of
centers located in Japan,
China, and India
3051 MV machines
identiﬁed, high country-
to-country disparity in
number of machines per
million population
Radiation oncologists and
therapists serve in multiple
roles; only 17 countries
meet human personnel
guidelines
Little known about types of
plans delivered
Latin
America &
Caribbean
470 RT centers, most
densely available in
Argentina, Chile, Panama,
Uruguay, and Venezuela
710 MV machines, 44% linear
accelerators; estimated
100 more machines
needed
69% more radiation
oncologists, 146% more
medical physicists, and
109% more RT technologists
needed
Only 3% of centers able to
generate IMRT plans
North
America
3388 RT centers between
United States (3331) and
Canada (57)
4240 MV machines between
United States (3956) and
Canada (284), 96% are
linear accelerators
4236 radiation oncologists,
robust medical physics
training programs
Quality assurance measures
not well described; many
centers perform advanced
RT techniques (IMRT, SABR)
RT, radiotherapy; MV, megavoltage; GNI, gross national income; IMRT, intensity-modulated radiotherapy; SABR, stereotactic ablative
radiotherapy.
24 Rodin et al Journal of Thoracic Oncology Vol. 11 No. 1disparity in distribution of RT capacity was also noted in
the Health Economics in Radiation Oncology project.23
Equipment. A total of 3157 megavoltage machines serve
an anticipated 2.8 million European patients with cancer.
On the basis of the Quantiﬁcation of Radiotherapy
Infrastructure and Stafﬁng Needs benchmarks, this rep-
resents a 19% unmet need for RT throughout Europe.24
Countries with a higher GNI (>$12,476 [U.S.] per capita
per year) serve approximately 400 to 450 patients per
machine per year, whereas countries with a lower GNI
treat signiﬁcantly more patients per machine. Although
92% of machines in Europe are linear accelerators, the
quality of machines (e.g., age, condition, treatment
techniques such as IMRT) and quality assurance mea-
sures used are not well described.25
Human Resources. There are approximately 6000 ra-
diation oncologists, 3000 medical physicists, and 10,000
RT technologists in Europe.22 Country-to-country varia-
tion in licensing requirements and clinical responsibilities
delegated to each discipline exists.Africa
Infrastructure. According to DIRAC, only 23 of 52 coun-
tries in Africa have RT centers, with a total of 160 RT cen-
ters for the continent.26,27 The 29 countries with no
machines account for 20%of the total Africanpopulation.27The small number of centers in such a large continent
contributes signiﬁcantly to lack of access and awareness.
Equipment. Of the 277 megavoltage machines in total,
32% (88 machines) are cobalt-60 units and 68% (189
machines) are linear accelerators.27 The distribution of
RT equipment is heavily weighted toward southern and
northern Africa, with 33% of the machines in South Af-
rica and 27% in Egypt alone. Despite the gradual in-
crease in RT centers and numbers of machines, waiting
times for these machines continue to be long. Among the
megavoltage machines, little is known regarding the
types of plans delivered (i.e. IMRT versus 3D-CRT).
Human Resources. The available information on the
number of professionals able to deliver RT in Africa and
available training programs is limited. The information
that does exist dates back to 1994, when South Africa
reported a total of 58 practicing radiation oncologists,
190 therapy radiographers, and 30 medical physicists.28
In 2011, a review article noted that “training facilities in
cancer diagnosis and management” in Africa were few
and found only in Algeria, Egypt, Libya, Morocco, Nigeria,
South Africa, and Zimbabwe.29Asia
Infrastructure. The most recent review of RT capacity
in the Asia and Paciﬁc region was published in 2001 by
January 2016 RT for NSCLC in Minimal Resource Settings 25the International Atomic Energy Agency (IAEA).30 The
17 countries included in the review hosted a total of
1462 RT centers. The highest numbers of RT centers
were found in Japan (611), China (453), and India (188).
Despite rapid increases in RT centers and machines in
China and India, both countries are still in need of
further treatment capacity.21,30,31
Equipment. A total of 3051 megavoltage machines were
identiﬁed among 17 countries included in the 2001 IAEA
review.30 Little is known regarding the types of RT plans
that are run on these machines. At the time of the review,
New Zealand had the greatest number of machines per
million people (7.39); in contrast, the rates in under-
equipped countries were much lower: Bangladesh
(0.09), Indonesia (0.12), and Vietnam (0.14). Even
among countries with signiﬁcant numbers of mega-
voltage machines, such as Turkey, linear accelerators
have been found to be concentrated in urban areas, with
large underserved regions in between.32 Since the 2001
review, many countries have had rapid increases in
numbers of megavoltage machines. India, which had only
35 linear accelerators in 2001, was found to have 232 in
2010.33
Human Resources. Although marked increases in the
RT workforce have been seen in many countries such as
India,33 radiation oncologists and therapists are limited
in most countries and frequently perform multiple roles
in RT delivery that would otherwise be divided among
many specialties in developed countries.30 Several
training programs are available or launching in
Cambodia, Indonesia, Turkey, and more human re-
sources are needed throughout the Asia and Paciﬁc
Region.32,34,35
Latin America and the Caribbean
Infrastructure. In this large region encompassing Cen-
tral America, South America, and the Caribbean coun-
tries, 589 million people live in primarily LMICs. A 2004
survey of 19 Latin American countries identiﬁed 470 RT
centers in total.36 Only ﬁve countries—Argentina, Chile,
Panama, Uruguay, and Venezuela—had more than one
center per million people, whereas some countries (e.g.,
Haiti) had no centers whatsoever.21
Equipment. In 2004, there were 710 megavoltage ma-
chines among 19 Latin American countries surveyed:
314 machines (44%) were linear accelerators and 396
machines (56%) were cobalt-60 units.36 The number of
machines remains insufﬁcient, with an estimated 100
more teletherapy machines required to meet the IAEA
guidelines.36 Only approximately 3% of the centers havethe ability to generate and deliver more advanced IMRT
plans.36 Some countries are actively investing in RT re-
sources. In 2013, Brazil’s Ministry of Health pledged to
purchase 80 new linear accelerators.37
Human Resources. In 2004, the 19 countries studied
had 933 radiation oncologists, 357 medical physicists,
and 2300 radiation technologists.36 Only 25% of the RT
centers had a full-time physicist, a functional simulator,
and the ability to create blocks. Training programs for
radiation oncology are on the rise, however. In 2004, 12
of 18 countries offered radiation oncology training
through a total of 35 institutions.36 Only 7 of 18 coun-
tries have a formal medical physics training program at
22 centers.
North America
The United States and Canada are HICs with well-
established RT infrastructure, equipment, and human
resources. We therefore provide only a brief review of
RT capacity in this region. The United States currently
has 3331 RT centers registered with DIRAC, and Canada
has 57 RT centers.38 Both countries have well above the
European Society for Radiotherapy and Oncology–
Quantiﬁcation of Radiotherapy Infrastructure and
Stafﬁng Needs guideline of 5.5 megavoltage machine
per million people, although regional variations in ac-
cess do exist. Many centers perform a variety of
advanced RT delivery techniques (i.e., IMRT, 3D-CRT,
stereotactic ablative radiotherapy). Published guide-
lines on quality assurance standards, such as the
Technical Quality Control Guidelines, which are pub-
lished by the Canadian Partnership for Quality Radio-
therapy, now exist.39
Strategies for RT delivery in minimal-
resource settings
It is evident that delivery of RT for lung cancer in
LMICs, including access to care, quality of care, and
economic efﬁciency, must be improved.40 In addition to
more RT resources, access to appropriate lung cancer
care requires a functional cancer control system and
health care system. This includes sufﬁcient pathology,
radiology, surgery, and internal medicine services, as
well as sufﬁcient drugs, medical supplies and equipment,
primary care, and palliative care.
Access is a multidimensional issue that includes
availability of RT equipment, human resources, accessi-
bility of RT centers, affordability of services, and
awareness of the importance of and appropriate use of
RT.41 Implementation of universal health coverage,
coupled with a cancer registry system to understand in-
country disease patterns, is an important step to address
Table 2. Resource-tiered technological guidelines
Indications Simulation
Treatment
technique
Oncology
center
Palliative
treatment of
locally advanced
primary and
metastatic lung
tumors
2D and CT
simulation
2D treatment
(rectangular
portals) and
3D CRT
Tier 1a
Routine radical
radiotherapy and
chemoradiation
of lung cancers
CT simulation 3D CRT Tier 2b
Complex cases
of radical
radiotherapy and
chemoradiation
CT simulation IMRT and
IGRT
Tier 3c
Specialized
techniques such
as SABR
CT simulation,
including 4D
techniques
IMRT, IGRT,
and 4D
treatment
Tier 3c
aTier 1, basic oncology center with cobalt machine.
bTier 2, intermediate oncology center with basic linear accelerator
and CT-based simulation.
cTier 3: advanced- level oncology center with linear accelerators,
CT simulation, and image guidance.
2D, two-dimensional; CT, computed tomography; 3D CRT, three-
dimensional conformal therapy; 4D, four-dimensional; IMRT,
intensity-modulated radiotherapy; IGRT, image-guided radio-
therapy; SABR, stereotactic ablative radiotherapy.
Table 3. Current international initiatives to address global
radiotherapy needs
Program
Region of
Origin
Year
Created Purpose
Programme
of Action
for Cancer
Therapy
France;
International
Atomic Energy
Association
2004 Increase access to
RT machines for
member states
Global Task
Force on
Radiotherapy
for Cancer
Control
Geneva,
Switzerland;
Union for
International
Cancer Control
2014 Develop an
investment
framework to
demonstrate the
health and
economic
beneﬁts resulting
from scaling up
RT capacity
International
Cancer Expert
Corps
United States;
National
Institutes of
Health
2014 Create a network
of cancer
professionals
to develop
sustainable
expertise for
better cancer
care
26 Rodin et al Journal of Thoracic Oncology Vol. 11 No. 1many of these issues.42 It is essential that any im-
provements in RT capacity be made through a compre-
hensive quality assurance and quality control process. As
RT resources for lung cancer expand, maintaining this
standard will require activities ensuring quality and
safety, including activities such as rigorous training,
dosimetry audits, accreditation, continuing medical ed-
ucation, and peer review.43
With regard to economic efﬁciency, resource-tiered
planning of treatment resources for lung cancer and
national cancer control planning are important
(Table 2). Despite the considerable variability with re-
gard to resource capability, tiered frameworks can
assist hospitals and planners in making appropriate
choices. Such practice has been similarly adopted by the
Breast Global Health Initiative, in which four levels of
health care resources, depending on the country’s
resource capacity, were developed.44 Guidance on lung
cancer is already available from an IAEA task force,
although some updating is required.45 Ensuring timely
diagnosis and early detection would probably also
minimize required treatment resources and improve
effectiveness of therapy. Scientiﬁc and technological
innovations, such as the use of shorter fractionation
schedules in cases in which evidence on its safety and
efﬁcacy exists, can also optimize the economics of
care.46Innovation
The complexity of operation and maintenance of
advanced RT delivery equipment has driven researchers
and vendors to investigate novel devices that may
broaden access. Two main approaches to increasing ac-
cess to external beam radiation units in LMICs have been
proposed47,48: (1) development of enhanced cobalt 60
(Co-60) units capable of modern dose delivery and (2)
manufacture of simpler robust linear accelerators
(linacs) that can operate in locations with problematic
infrastructure or in problematic environments. Each
path has supporters and critics.47–49
During a three-decade decline of use in HICs, Co-60
delivery has acquired a reputation of being inferior
and having no place in modern RT. However, some re-
searchers have advocated that the dose delivery limita-
tions have not resulted from the characteristics of the
Co-60 beam (such as beam penetration and penumbra
width), but rather from a lack of machine develop-
ment.49,50 Recent modeling studies and investigations on
modiﬁed Co-60 units have shown that the improved
conformal delivery expected in modern RT is achievable
in a Co-60–based IMRT setting.50–55
Linac suppliers have been developing units that are
more conducive to use in LMICs. Unfortunately, however,
much of this development is proprietary and not yet
described in the literature. One approach has been to
develop simple low-energy units with intentional
removal of components that require more careful
maintenance or frequent repair. This approach may
result in linac units with limitations similar to those
January 2016 RT for NSCLC in Minimal Resource Settings 27of the more advanced Co-60 units that are now avail-
able.47,48 The motivation to bring the number of radia-
tion units to the level required to meet the current and
projected global needs will drive the development of
both Co-60 units and linacs that are more appropriate
for LMICs. Analysis in the literature suggests that LMICs
would likely beneﬁt from a mixed approach using both
Co-60– and linac-based devices.47,48
Current international initiatives
A number of international initiatives have been
spearheaded by United Nations agencies and nongov-
ernmental agencies to address the global shortfall of RT
capacity (Table 3). Through its Programme of Action for
Cancer Therapy, the IAEA has engaged at the country
level to help member states’ governments build RT
services. This initiative is being undertaken in the
context of local cancer control programs by providing
expert technical advice on and assistance with the pro-
curement of equipment.56
Unfortunately, the urgency and necessity to build RT
capacity in LMICs has still not been universally recog-
nized within the health and development community. To
promote awareness and action to address this unmet
need, the Union for International Cancer Control
launched the Global Task Force on Radiotherapy for
Cancer Control in early 2014. This task force is devel-
oping an investment framework to demonstrate the
health and economic beneﬁts that would result from the
scaling up of capacity for RT in LMICs.57 In late 2014, the
International Cancer Expert Corps was established to
promote the development of a high-quality sustainable
workforce to improve cancer care capability and capac-
ity within LMICs.58,59 The goal of the International Can-
cer Expert Corps is to develop a global workforce that
includes oncologists, pathologist, radiologists, and
nurses who would be provided with training and sus-
tainable clinical support in LMICs.
Many academic centers and national bodies are
responding to the global health interest of their trainees
by establishing collaborations with international in-
stitutions. The hope is that such collaborations will
facilitate greater exchange of knowledge between estab-
lished cancer treatment centers and limited resource
settings.58,60 One such example is the University of
Pennsylvania and Massachusetts General Hospital part-
nership with the oncology department in Botswana.61,62
The Canadian Association of Radiation Oncology Inter-
national Communications Working Group and the
American Society for Therapeutic Radiation Oncology
have both launched scholarship programs to enable ra-
diation oncology trainees to improve their knowledge on
global health issues and challenges by participating in
research and clinical work in low- resource settings.63,64The development of bilateral exchange programs with
involved centers would be an important next step.
Conclusion
Treatment of NSCLC requires access to RT, surgery,
systemic therapy, and a wide range of supportive and
diagnostic services. This multimodal approach is available
in most developed countries, but little or no access to RT
exists in many LMICs. Priorities include investing in both
human capacity and treatment resources, ensuring quality
of care, providing guidance on priority setting with limited
resources, and fostering innovation to increase the eco-
nomic efﬁciency of RT delivery. Such technical innovation
could simplify RT planning and treatment, particularly in
regions that have not yet implemented basic in-
frastructures and systems to deliver RT. Although smoking
cessation is an essential goal to prevent cancer in LMICs,
such efforts will not diminish the increasing number of
patients in whom development of NSCLC is expected over
the next few decades and who will require treatment.
ScalingupRT in these regions isurgentlyneeded toprevent
unnecessary morbidity and mortality due to NSCLC.
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